Ann: FDA Grants Rare Pediatric Disease Designation for Revascor, page-89

Maybe stop peppering other posters with replies like:

"Look up accelerated approval. On the FDA website. It doesn't mean what you think it means"
"You should probably read up on these things."
"Share price getting hyped by people who don't understand the process."

Some example of your posts just on this thread alone.

You didn't once mention (or I suspect consider) the re-evaluation of either MSB's IP, or likely change of attributed probability of commercial execution by MSB with the FDA on this designation, used by most analysts in DCF valuations or the like...that's why the price is jumping. Only the most ignorant think the price jumped for any other reason.

MSBer's are generally some of the most informed retail investors of FDA regulatory processes and procedure, from their sheer suffering at the inconsistency and complex ambiguity of it.